Fluvoxamine-a new serotonin re-uptake inhibitor: first clinical and psychometric experiences in depressed patients
- PMID: 335026
- DOI: 10.1007/BF01252962
Fluvoxamine-a new serotonin re-uptake inhibitor: first clinical and psychometric experiences in depressed patients
Abstract
The clinical efficacy of fluvoxamine (DU 23000)--the first selective serotonin re-uptake inhibitor of the new class of 2-aminoethyloximethers of aralkylketones was investigated in endormorphous depressed patients during 5 weeks treatment with mean daily dosages of approximately 150 mg DU 23000. A marked and statistically significant improvement of the overall and detailed psychopathology was noted by means of the Global Clinical Impression and Hamilton Rating Scale as early as in the first week of drug administration. Bipolar patients tended to improve more than unipolar ones, retarded depressions more than agitated ones. An additional anxiolytic medication was occasionally required. The drug was well tolerated. Psychometric and laboratory findings did not show any significant changes. The findings are discussed in the light of the indolamine hypothesis of depression.
Similar articles
-
Fluvoxamine and clomipramine in depressed patients. A double-blind clinical study.Acta Psychiatr Scand. 1981 Jul;64(1):1-11. doi: 10.1111/j.1600-0447.1981.tb00756.x. Acta Psychiatr Scand. 1981. PMID: 6172005 Clinical Trial.
-
Clinical trials of fluvoxamine vs chlorimipramine with single and three times daily dosing.Br J Clin Pharmacol. 1983;15 Suppl 3(Suppl 3):427S-431S. doi: 10.1111/j.1365-2125.1983.tb02133.x. Br J Clin Pharmacol. 1983. PMID: 6407503 Free PMC article. Clinical Trial.
-
A double-blind comparative study of the clinical efficacy of fluvoxamine and chlorimipramine.Br J Clin Pharmacol. 1983;15 Suppl 3(Suppl 3):419S-425S. doi: 10.1111/j.1365-2125.1983.tb02132.x. Br J Clin Pharmacol. 1983. PMID: 6407502 Free PMC article. Clinical Trial.
-
Which antidepressants flick the switch?Aust N Z J Psychiatry. 2003 Aug;37(4):464-8. doi: 10.1046/j.1440-1614.2003.01207.x. Aust N Z J Psychiatry. 2003. PMID: 12873332 Review.
-
Fluvoxamine as an antiobsessional agent.Psychopharmacol Bull. 1989;25(1):31-5. Psychopharmacol Bull. 1989. PMID: 2505302 Review.
Cited by
-
Therapeutically targeting the consequences of HIV-1-associated gastrointestinal dysbiosis: Implications for neurocognitive and affective alterations.Pharmacol Biochem Behav. 2023 Aug;229:173592. doi: 10.1016/j.pbb.2023.173592. Epub 2023 Jun 29. Pharmacol Biochem Behav. 2023. PMID: 37390973
-
Fluvoxamine. An updated review of its pharmacology, and therapeutic use in depressive illness.Drugs. 1993 Nov;46(5):895-924. doi: 10.2165/00003495-199346050-00008. Drugs. 1993. PMID: 7507038 Review.
-
A placebo controlled study of the cardiovascular effects of fluvoxamine and clovoxamine in human volunteers.Br J Clin Pharmacol. 1982 Dec;14(6):805-8. doi: 10.1111/j.1365-2125.1982.tb02040.x. Br J Clin Pharmacol. 1982. PMID: 6817771 Free PMC article. Clinical Trial.
-
Clovoxamine and fluvoxamine-2 biogenic amine re-uptake inhibiting antidepressants: quantitative EEG, psychometric and pharmacokinetic studies in man.J Neural Transm. 1980;49(1-2):63-86. doi: 10.1007/BF01249190. J Neural Transm. 1980. PMID: 6777458 Clinical Trial.
-
Cardiac effects of antidepressant drugs. A comparison of the tricyclic antidepressants and fluvoxamine.Br J Clin Pharmacol. 1983;15 Suppl 3(Suppl 3):439S-445S. doi: 10.1111/j.1365-2125.1983.tb02135.x. Br J Clin Pharmacol. 1983. PMID: 6407505 Free PMC article.
References
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
